DuoGenic StemCells corporation Overview
Get informed when a big investor buys or sells
+ Follow-186.72%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 7607.TWO is -186.72%. That is below the sector sector average of 11.64%. Investors often review this figure alongside DuoGenic StemCells corporation's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 7607.TWO currently prints -186.72% for ROE, while the sector average sits near 11.64%. That is roughly 1704.6% below the sector mean. Large gaps often invite a closer look at DuoGenic StemCells corporation's growth, margins, and balance sheet.
Return on Equity shows how effectively DuoGenic StemCells corporation converts resources into returns. At -186.72%, 7607.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 7607.TWO's ROE (-186.72%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
